Keytruda has struggled to make an impact in prostate cancer, and the disease does not feature on the drug's very long list of approved indications, despite considerable clinical testing on Merck's ...

US-based pharmaceutical company MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

Merck & Co's KEYNOTE-158 trial of Keytruda has underpinned another FDA approval, this time for the PD-1 inhibitor as a single-agent therapy as a therapy for endometrial cancer with certain genetic ...